AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE
NEW YORK and LONDON, June 28, 2019 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan …
[Read more...] about Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering
Dear Shareholder, We would like to inform shareholders that we shall be unable to hold our forthcoming Annual General Meeting at the place stated in the …
Part A of a safety and efficacy study successfully completed with nomacopan eye drops which were well tolerated with no serious adverse events. Improvement in …
Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trials Further clinical data from BP …
Notice of Annual Shareholders Meeting 2019 Change of AGM Venue Proxy Form Consolidated Annual Report and Financial Statements Dear Shareholders of …
[Read more...] about NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2019
